TFC Financial Management’s Neurocrine Biosciences NBIX Stock Holding History

TFC Financial Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$675	Hold	4	–	–	﹤0.01%	698
2026 Q1	$527	Hold	4	–	–	﹤0.01%	703
2025 Q4	$568	Hold	4	–	–	﹤0.01%	681
2025 Q3	$562	Hold	4	–	–	﹤0.01%	699
2025 Q2	$503	Buy	+4	New	+$459	﹤0.01%	679
2024 Q3	–	Sell	-4	Closed	-$551	–	1066
2024 Q2	$551	Buy	4 +3	+300%	+$411	﹤0.01%	623
2024 Q1	$138	Buy	+1	New	+$137	﹤0.01%	781
2023 Q2	–	Sell	-160	Closed	-$16.2K	–	715
2023 Q1	$16.2K	Buy	+160	New	+$16.6K	﹤0.01%	330

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

SCP

Seizert Capital Partners Birmingham, Michigan $2.42B AUM 22.12% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

TFC Financial Management's NBIX Position: Q2 2026 in Review

TFC Financial Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 4 shares worth $675. The position accounts for ﹤0.01% of the portfolio, ranked #698.

TFC Financial Management first reported a position in NBIX in Q1 2023 and has held it in 8 quarters since. The position peaked at $16.2K in Q1 2023. 313 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

TFC Financial Management held 4 shares of Neurocrine Biosciences worth $675 as of Q2 2026.
TFC Financial Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of TFC Financial Management's portfolio in Q2 2026, its #698 holding.
TFC Financial Management first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 8 quarters since.
TFC Financial Management's Neurocrine Biosciences position peaked at $16.2K in Q1 2023.
313 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on TFC Financial Management's 13F filing for Q2 2026, filed 23 Jul 2026.